Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TVB-3567 · 1 trial · 1 indication
Area under the concentration-time curve from time zero until the last observed concentration
Area under the concentration-time curve from time zero to infinity
Maximum concentration measurement in plasma
| Arm | Type | Description |
|---|---|---|
| Part A (SAD in Healthy Participants) | EXPERIMENTAL | - |
| Part B (Food Effect) | EXPERIMENTAL | - |
| Part C (MAD in Healthy Participants) | EXPERIMENTAL | - |
| Part D (MAD in Acne Participants) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TVB-3567 | DRUG | Orally administered capsule |
| Placebo | DRUG | Orally administered capsule |
Inclusion Criteria: Healthy Participants (Parts A, B and C) 1. Healthy, adult, male or female 18-55 years of age 2. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 3. Medically healthy with no clinically significant medical history 4. Understands the study procedures in the informed consent form (ICF)...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 3 | PHASE1 | Acne mRNA vaccine |
| Hoth Therapeutics, Inc. | HOTH | 1 | PHASE2 | HT-001 |
| Sagimet Biosciences Inc. Class A | SGMT | 1 | PHASE1 | TVB-3567 |
TVB-3567 is an investigational small molecule being developed for the treatment of acne. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in healthy participants with or without acne to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
TVB-3567 targets FASN, a protein involved in fatty acid synthesis. By inhibiting FASN, the drug may reduce sebum production, which is a key factor in the development of acne. This mechanism is being investigated in early-stage clinical trials to determine its safety and efficacy.
TVB-3567 is being developed by Sagimet Biosciences Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and tolerability in healthy participants with or without acne.
TVB-3567 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics.
TVB-3567 is being studied in a Phase 1 clinical trial with the identifier NCT06989840. This randomized, double-blind, controlled study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of TVB-3567 in healthy participants with or without acne. The trial is recruiting 128 participants in the United States and Australia.